About This Program
GLP-1 Injections at Soboba
GLP-1 receptor agonists have transformed the landscape of medical weight loss in Orange County and across the country. These medications work by mimicking glucagon-like peptide-1 — a naturally occurring gut hormone that regulates appetite, slows gastric emptying, and signals the brain's hypothalamus to reduce hunger throughout the day. The result is a sustained, clinically meaningful reduction in caloric intake that makes it dramatically easier to adhere to a reduced-calorie program and reach a healthier body weight. Unlike older stimulant-based appetite suppressants, GLP-1 medications work in harmony with your body's own hormonal pathways — producing weight loss that compounds over time rather than plateauing after a few weeks. The clinical trial data behind this drug class is among the strongest in the history of obesity medicine. At Soboba Medical Weight Loss in Orange County, our physicians prescribe two GLP-1 medications for physician-supervised weight management: Ozempic (semaglutide) and Mounjaro (tirzepatide), both dispensed under direct physician supervision with ongoing monitoring. Semaglutide produced an average of 14.9% body weight loss over 68 weeks in the landmark STEP 1 clinical trial published in the New England Journal of Medicine — compared to just 2.4% in the placebo group. Tirzepatide, which uniquely activates both the GLP-1 and GIP receptors simultaneously, produced an average of 20.9% body weight loss in the SURMOUNT-1 trial, with 63% of participants at the highest dose losing 20% or more of their body weight. These results had previously been associated only with bariatric surgery, not medication. Choosing the right GLP-1 medication depends on your medical history, prior weight loss experience, and individual physiology — which is why every Soboba patient begins with a thorough physician evaluation before any prescription is written. Our physicians assess your full health profile, review current medications, evaluate your cardiovascular and thyroid history, and discuss your weight loss goals in detail before recommending semaglutide, tirzepatide, or another approach entirely. If you have tried a GLP-1 program before without reaching your target weight, switching to a dual-receptor agonist or adjusting your titration schedule may be the step forward you need. Your first consultation is completely free, and same-week appointments are available at all three of our Orange County locations.
How It Works
Your Soboba physician conducts a thorough evaluation before any GLP-1 prescription is written — reviewing your health history, cardiovascular profile, thyroid function, current medications, and prior weight loss experience to determine whether semaglutide or tirzepatide is the right fit for your body.
GLP-1 medications activate receptors in the gut and brain that regulate hunger and satiety — slowing gastric emptying, reducing post-meal blood glucose spikes, and signaling the hypothalamus to suppress appetite continuously, not just at mealtimes.
Soboba prescribes both leading GLP-1 medications: Ozempic (semaglutide), with semaglutide producing 14.9% average body weight loss over 68 weeks in the STEP 1 trial, and Mounjaro (tirzepatide), which adds GIP receptor activation for stronger appetite suppression — with tirzepatide producing an average of 20.9% weight loss in SURMOUNT-1.
All GLP-1 programs at Soboba begin at the lowest effective starting dose and titrate upward gradually — a carefully managed process that minimizes nausea and GI side effects while allowing your body to adjust to the medication at each stage.
Monthly physician check-ins are built into every GLP-1 program — allowing your Soboba doctor to assess your response to the current dose, adjust as needed, provide nutritional guidance, and monitor for any side effects that require clinical attention.
Patients who have plateaued or had suboptimal results on one GLP-1 medication often find meaningful additional progress by switching options — your Soboba physician will evaluate whether a change is appropriate and manage any transition safely.
All Soboba Programs Include
Ready to Start?
Same-week appointments available. Call any of our 3 Orange County locations — first consultation is free.
Key Benefits
Start Your GLP-1 Injections Program Today
GLP-1 receptor agonists are the most clinically proven weight loss medications available today — and at Soboba Medical Weight Loss, they're paired with the physician supervision, dose titration, and ongoing monitoring they require to be used safely and effectively. Our physicians will evaluate your medical profile and recommend the right GLP-1 option for your body and goals. Call any of our three Orange County locations today — your first consultation is completely free and same-week appointments are available.
Call Now — Free ConsultationSame-week appointments available · No contracts · No startup fees
Individual results may vary. This content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. All programs are supervised by licensed physicians. These statements have not been evaluated by the Food and Drug Administration.
Choosing Your Medication
Semaglutide vs. Tirzepatide
Both semaglutide (the active ingredient in Ozempic) and tirzepatide (the active ingredient in Mounjaro) are GLP-1 class medications prescribed at Soboba — but they work differently and produce different average results. Your physician will recommend the right option based on your health history, prior medication experience, and goals.
For a deeper side-by-side comparison including side effects and candidacy, see our guide: Mounjaro vs. Ozempic: Key Side Effects and Results. You can also explore each medication individually: Ozempic program · Mounjaro program.
What to Expect
Side Effects and Tolerability
GLP-1 medications are well-tolerated by most patients when doses are introduced gradually. Side effects occur primarily during the titration period and typically improve as your body adjusts to each dose level. Your Soboba physician manages titration carefully and can slow the pace if side effects are significant.
Common Side Effects
Most frequent during dose titration. Usually improve within a few weeks at each dose level.
Serious — Know Before Starting
Your physician screens for contraindications before prescribing and monitors throughout your program.
Black box warning: GLP-1 receptor agonists are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), based on animal studies. Your Soboba physician will review your thyroid history before prescribing.
Are You a Candidate?
Who GLP-1 Programs Work Best For
GLP-1 programs are most appropriate for patients who meet specific medical criteria. These are general guidelines — only a physician consultation confirms actual candidacy for your specific health profile.
BMI ≥ 30, or BMI ≥ 27 with at least one weight-related condition (hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea)
Prior diet and exercise attempts have not produced adequate or lasting weight loss
No personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2)
No history of acute pancreatitis or current severe gastrointestinal disease
Not currently pregnant or planning to become pregnant during treatment
Concurrent medications reviewed for potential interactions (insulin and sulfonylureas in particular)
The only way to confirm candidacy is a physician evaluation. Your first consultation at Soboba is completely free — call any of our three Orange County locations to get started.
Related Programs
Also Consider These Options
💊
Ozempic (Semaglutide)
The original GLP-1 medication for weight loss. 14.9% average body weight loss in the STEP 1 clinical trial. The most established GLP-1 program at Soboba.
🏆
Mounjaro (Tirzepatide)
Dual GLP-1 + GIP receptor agonist — the most powerful weight loss medication available. 20.9% average weight loss in SURMOUNT-1.
🔬
GLP-3 Injections
Retatrutide — the next generation triple-receptor agonist currently in Phase 3 clinical trials. Learn about what's coming next in weight loss medicine.